Milestone Pharmaceuticals announced it granted 288,000 stock options to six new employees as an inducement to join the company. The options have an exercise price of $1.32 per share, matching the closing price on July 1, 2026, and will vest over four years. This grant follows Nasdaq Listing Rule 5635(c)(4), which allows inducement awards to attract new talent. Milestone focuses on cardiovascular medicines, with its lead product CARDAMYST™ approved for treating certain heart rhythm conditions.
Pepeto, a new Ethereum-based cryptocurrency, is about to debut on Binance after raising $10.37 million in its presale, signaling strong investor interest. The project offers a fully built DeFi platform, addressing utility gaps that Cardano has strugg...
Edelson Lechtzin LLP is investigating whether Swatch Group raised prices on watches and jewelry due to tariffs imposed under the Trump administration and failed to refund customers after the U.S. Supreme Court invalidated those tariffs in February 20...
Edelson Lechtzin LLP is investigating Hermès for allegedly raising prices on luxury goods due to tariffs imposed during 2025 and not refunding customers after the U.S. Supreme Court invalidated those tariffs in February 2026. The investigation focuse...
The Canadian federal government has pledged $500 million to support the development of the Red Chris Block Cave project, a copper-gold mining operation by Imperial Metals and Newmont Corporation. This funding is part of the Canada-British Columbia Co...
Ethereum has traded in a narrow range around $1,600 after falling to $1,510, with a recent $26.87 million whale transfer to an exchange not causing immediate price drops. The whale, Satofashi, who bought ETH at an average price of $1,749, may be repo...
